H.(T.) v. Novartis Pharm. Corp.

California Supreme Court

H.(T.) v. Novartis Pharm. Corp.

371 P.3d 241, 203 Cal. Rptr. 3d 22

CourtCalifornia Supreme Court

DecidedJune 8, 2016

DocketNo. S233898.

StatusPublished

Cited by1 cases

This text of 371 P.3d 241 (H.(T.) v. Novartis Pharm. Corp.) is published on Counsel Stack Legal Research, covering California Supreme Court primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook

H.(T.) v. Novartis Pharm. Corp., 371 P.3d 241, 203 Cal. Rptr. 3d 22 (Cal. 2016).

Pincite

Opinion

The applications to appear as counsel pro hac vice are granted. The petition for review is granted. The issue to be briefed and argued is limited to the following: May the brand name manufacturer of a pharmaceutical drug that divested all ownership interest in the drug be held liable for injuries caused years later by another manufacturer's generic version of that drug?

WERDEGAR, J., was recused and did not participate.

Free access — add to your briefcase to read the full text and ask questions with AI

The applications to appear as counsel pro hac vice are granted. The petition for review is granted. The issue to be briefed and argued is limited to the following: May the brand name manufacturer of a pharmaceutical drug that divested all ownership interest in the drug be held liable for injuries caused years later by another manufacturer's generic version of that drug?

WERDEGAR, J., was recused and did not participate.

Cite This Page — Counsel Stack

Bluebook (online)

371 P.3d 241, 203 Cal. Rptr. 3d 22, Counsel Stack Legal Research, https://law.counselstack.com/opinion/ht-v-novartis-pharm-corp-cal-2016.

Opinion

Related

Cite This Page — Counsel Stack